Journal of Renal Nutrition
Volume 15, Issue 2 , Pages 195-203 , April 2005

Dyslipidemia and nephrotic syndrome: Recent advances

  • Florian Kronenberg, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Florian Kronenberg, MD, Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Schöpfstr. 41, A-6020 Innsbruck, Austria.

References 

  1. Kronenberg F , Lingenhel A , Lhotta K , et al.   The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome . Kidney Int . 2004;65:606–612
  2. Kronenberg F , Lingenhel A , Lhotta K , et al.   Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome (Impact on lipid-lowering therapy?) . Kidney Int . 2004;66:348–354
  3. Joven J , Villabona C , Vilella E , et al.   Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome . N Engl J Med . 1990;323:579–584
  4. Warwick GL , Packard CJ , Demant T , et al.   Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria . Kidney Int . 1991;40:129–138
  5. De Sain-van der Velden M , Kaysen GA , Barrett HA , et al.   Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis . Kidney Int . 1998;53:994–1001
  6. Vaziri ND , Liang KH . Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis . Kidney Int . 1995;48:1979–1985
  7. Liang K , Vaziri ND . HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia . Kidney Int . 2003;64:192–198
  8. Vaziri ND , Sato T , Liang K . Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis . Kidney Int . 2003;63:1756–1763
  9. Vaziri ND , Liang K . Up-regulation of acyl-coenzyme A (Cholesterol acyltransferase (ACAT) in nephrotic syndrome) . Kidney Int . 2002;61:1769–1775
  10. Vaziri ND , Liang KH . Acyl-coenzyme A (Cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-density lipoprotein receptor deficiencies in nephrotic syndrome) . Circulation . 2004;110:419–425
  11. Appel GB , Blum CB , Chien S , et al.   The hyperlipidemia of nephrotic syndrome (Relation to plasma albumin concentration, oncotic pressure and viscosity) . N Engl J Med . 1985;312:1544–1548
  12. Gherardi E , Rota E , Calandra S , et al.   Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome . Eur J Clin Invest . 1977;7:563–570
  13. Acton S , Rigotti A , Landschulz KT , et al.   Identification of scavenger receptor SR-BI as a high density lipoprotein receptor . Science . 1996;271:518–520
  14. Vaziri ND , Liang K , Parks JS . Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome . Am J Physiol Renal Physiol . 2001;280:F823–F828
  15. Deighan CJ , Caslake MJ , McConnell M , et al.   Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1 . Kidney Int . 2000;58:1238–1246
  16. Liang K , Vaziri ND . Down-regulation of hepatic lipase expression in experimental nephrotic syndrome . Kidney Int . 1997;51:1933–1937
  17. Kaysen GA , Hoye E , Jones H . Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats . Am J Physiol . 1995;268:F532–F540
  18. Kaysen GA , Mehendru L , Pan XM , et al.   Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis . Am J Physiol . 1992;263:F335–F341
  19. Shearer GC , Stevenson FT , Atkinson DN , et al.   Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome . Kidney Int . 2001;59:179–189
  20. Garber DW , Gottlieb BA , Marsh JB , et al.   Catabolism of very low density lipoproteins in experimental nephrosis . J Clin Invest . 1984;74:1375–1383
  21. Vaziri ND . Molecular mechanisms of lipid disorders in nephrotic syndrome . Kidney Int . 2003;63:1964–1976
  22. Sato T , Liang K , Vaziri ND . Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis . Kidney Int . 2002;61:157–162
  23. Vaziri ND , Liang K . Down-regulation of VLDL receptor expression in chronic experimental renal failure . Kidney Int . 1997;51:913–919
  24. Vaziri ND , Kim CH , Phan D , et al.   Up-regulation of hepatic Acyl CoA (Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome) . Kidney Int . 2004;66:262–267
  25. Furukawa S , Hirano T , Mamo JC , et al.   Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis . Metabolism . 1990;39:101–107
  26. Utermann G . Lipoprotein(a) . In:  Scriver CR ,  Beaudet AL ,  Sly WS ,  Valle D editor. The metabolic and molecular bases of inherited disease . (ed 8).. New York: McGraw-Hill; 2000;p. 2753–2787
  27. Utermann G , Menzel HJ , Kraft HG , et al.   Lp(a) glycoprotein phenotypes (Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma) . J Clin Invest . 1987;80:458–465
  28. Danesh J , Collins R , Peto R . Lipoprotein(a) and coronary heart disease (Meta-analysis of prospective studies) . Circulation . 2000;102:1082–1085
  29. Craig WY , Neveux LM , Palomaki GE , et al.   Lipoprotein(a) as a risk factor for ischemic heart disease (Metaanalysis of prospective studies) . Clin Chem . 1998;44:2301–2306
  30. Sandholzer C , Saha N , Kark JD , et al.   Apo(a) isoforms predict risk for coronary heart disease (A study in six populations) . Arterioscler Thromb . 1992;12:1214–1226
  31. Wild SH , Fortmann SP , Marcovina SM . A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants . Arterioscler Thromb Vasc Biol . 1997;17:239–245
  32. Kronenberg F , Kronenberg MF , Kiechl S , et al.   Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis (Prospective results from the Bruneck Study) . Circulation . 1999;100:1154–1160
  33. Kronenberg F , Utermann G , Dieplinger H . Lipoprotein(a) in renal disease . Am J Kidney Dis . 1996;27:1–25
  34. Kronenberg F . Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease . Expert Rev Cardiovasc Ther . 2004;2:729–743
  35. Dieplinger H , Lackner C , Kronenberg F , et al.   Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a) . J Clin Invest . 1993;91:397–401
  36. Kronenberg F , Kuen E , Ritz E , et al.   Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure . J Am Soc Nephrol . 2000;11:105–115
  37. Wanner C , Rader D , Bartens W , et al.   Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome . Ann Intern Med . 1993;119:263–269
  38. Stenvinkel P , Berglund L , Heimburger O , et al.   Lipoprotein(a) in nephrotic syndrome . Kidney Int . 1993;44:1116–1123
  39. Kawasaki Y , Suzuki J , Nozawa R , et al.   Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid-sensitive nephrotic syndrome . Nephron . 2002;92:807–811
  40. Merouani A , Levy E , Mongeau JG , et al.   Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome . Clin Biochem . 2003;36:571–574
  41. De Sain-van der Velden MGM , Reijngoud DJ , Kaysen GA , et al.   Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome . J Am Soc Nephrol . 1998;9:1474–1481
  42. Kostner GM , Ibovnik A , Holzer H , et al.   Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard . J Lipid Res . 1999;40:2255–2263
  43. Marcovina SM , Albers JJ , Scanu AM , et al.   Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a) . Clin Chem . 2000;46:1956–1967
  44. Kronenberg F , Lingenhel A , Neyer U , et al.   Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients . Kidney Int . 2003;63(suppl 84):S113–S114
  45. Kostner GM , Gavish D , Leopold B , et al.   HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels . Circulation . 1989;80:1313–1319
  46. Scanu AM , Hinman J . Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels . Lipids . 2002;37:439–444
  47. Chen G , Paka L , Kako Y , et al.   A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion . J Biol Chem . 2001;276:49142–49147
  48. Zhang SH , Reddick RL , Piedrahita JA , et al.   Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E . Science . 1992;258:468–471
  49. Asami T , Ciomartan T , Hayakawa H , et al.   Apolipoprotein E epsilon 4 allele and nephrotic glomerular diseases in children . Pediatr Nephrol . 1999;13:233–236
  50. Attila G , Noyan A , Karabay BA , et al.   Apolipoprotein E polymorphism in childhood nephrotic syndrome . Pediatr Nephrol . 2002;17:359–362
  51. Bruschi M , Catarsi P , Candiano G , et al.   Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis . Kidney Int . 2003;63:686–695
  52. Kim SD , Kim IS , Lee BC , et al.   Apolipoprotein E polymorphism and clinical course in childhood nephrotic syndrome . Pediatr Nephrol . 2003;18:230–233
  53. Ruggenenti P , Mise N , Pisoni R , et al.   Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies . Circulation . 2003;107:586–592
  54. Hattori M , Chikamoto H , Akioka Y , et al.   A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children . Am J Kidney Dis . 2003;42:1121–1130
  55. Rodriguez-Iturbe B , Sato T , Quiroz Y , et al.   AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat . Kidney Int . 2004;66:668–675
  56. Berg AL , Nilsson-Ehle P , Arnadottir M . Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy . Kidney Int . 1999;56:1534–1543
  57. Arnadottir M , Berg AL , Dallongeville J , et al.   Adrenocorticotropic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients . Kidney Int . 1997;52:1651–1655
  58. Arnadottir M , Berg A-L , Kronenberg F , et al.   Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients (Relation to apolipoprotein(a) size polymorphism) . Metabolism . 1999;48:342–346

 The author’s work presented in this review was supported by the Austrian Science Fund, the Austrian National Bank, the Austrian Academy of Science, the Austrian Heart Fund, the Austrian Genome Research Programme GEN-AU (Project GOLD), and the Else Kröner-Fresenius Stiftung (Germany), which is highly appreciated.

PII: S1051-2276(04)00251-1

doi: 10.1053/j.jrn.2004.10.003

Journal of Renal Nutrition
Volume 15, Issue 2 , Pages 195-203 , April 2005

Article Tools

* Image Usage & Resolution